CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $9.44B, above the global median of $1.2B
- PositionReturn on equity is 26%, higher than 95% of its Medical Devices peers (median 3.2%)
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
9.44BUSDvs all stocks (USD)
Trailing P/E
25.59xvs Medical Devices peers
Revenue (TTM)
3.05BUSDvs all stocks (USD)
Profit Margin
12.29%vs Medical Devices peers
Beta
1.08xvs all stocks
52-Week Change
-56.17%vs all stocks
Market Capitalization
9.44BUSDvs all stocks (USD)
Enterprise Value
9.85BUSDvs all stocks (USD)
Trailing P/E
25.59xvs Medical Devices peers
Forward P/E
17.66xvs Medical Devices peers
PEG Ratio
0.0780xvs Medical Devices peers
Price to Sales (TTM)
3.09xvs Medical Devices peers
Price to Book (MRQ)
6.64xvs Medical Devices peers
Enterprise to Revenue
3.23xvs Medical Devices peers
Enterprise to EBITDA
16.03xvs Medical Devices peers
Gross Margin
70.18%vs Medical Devices peers
Profit Margin
12.29%vs Medical Devices peers
Operating Margin
16.18%vs Medical Devices peers
Return on Assets (TTM)
9.71%vs Medical Devices peers
Return on Equity (TTM)
26.02%vs Medical Devices peers
Revenue (TTM)
3.05BUSDvs all stocks (USD)
Revenue per Share (TTM)
43.62USDUpdated Sep 28, 2026Quarterly Revenue Growth
23.50%vs Medical Devices peers
Gross Profit (TTM)
2.17BUSDvs all stocks (USD)
EBITDA (TTM)
640.20MUSDvs all stocks (USD)
Net Income (TTM)
375.30MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
322.20%vs Medical Devices peers
Operating Cash Flow (TTM)
511.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
236.90MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
2.71BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
768.20MUSDFY2025 · Dec 31, 2025Gross Profit
1.94BUSDFY2025 · Dec 31, 2025Operating Income
473.80MUSDvs all stocks (USD)
Pre-tax Income
339.50MUSDFY2025 · Dec 31, 2025Income Tax Expense
92.40MUSDFY2025 · Dec 31, 2025Net Income
247.10MUSDFY2025 · Dec 31, 2025EBIT
398.90MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
600.70MUSDFY2025 · Dec 31, 2025Research & Development
301.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
1.17BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
34.70MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
59.40MUSDFY2025 · Dec 31, 2025EPS (Basic)
3.51USDFY2025 · Dec 31, 2025EPS (Diluted)
3.48USDFY2025 · Dec 31, 2025Basic Shares Outstanding
70.35MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
70.35MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
247.10MUSDFY2025 · Dec 31, 2025Operating Cash Flow
374.00MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
716.10MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
247.10MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
90.40MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
62.20MUSDFY2025 · Dec 31, 2025Stock-based Compensation
62.70MUSDFY2025 · Dec 31, 2025Other Non-cash Items
13.20MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-140.20MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
49.20MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.60MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-27.80MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Other Investing Activity
-3.30MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.30MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
506.10MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.21BUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-59.60MUSDFY2025 · Dec 31, 2025Other Financing Charges
-26.10MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-793.80MUSDFY2025 · Dec 31, 2025Shares Outstanding
69.35MSharesUpdated Sep 28, 2026Float Shares
69.06MSharesUpdated Sep 28, 2026Shares Short
5.08MSharesUpdated Sep 28, 2026Short Ratio
2.86daysvs all stocks
Short % of Shares Outstanding
8.27%vs all stocks
% Held by Insiders
0.33%vs all stocks
% Held by Institutions
107.11%vs all stocks
Total Cash (MRQ)
534.90MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.71USDUpdated Sep 28, 2026Total Debt (MRQ)
948.40MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.6669xvs Medical Devices peers
Current Ratio (MRQ)
2.48xvs Medical Devices peers
Book Value per Share (MRQ)
20.51USDUpdated Sep 28, 2026Total Assets
3.19BUSDvs all stocks (USD)
Total Current Assets
1.91BUSDFY2025 · Dec 31, 2025Total Liabilities
1.68BUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.28BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
995.00MUSDFY2025 · Dec 31, 2025Total Current Liabilities
680.10MUSDFY2025 · Dec 31, 2025Cash
138.70MUSDFY2025 · Dec 31, 2025Cash Equivalents
577.40MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
716.10MUSDFY2025 · Dec 31, 2025Accounts Receivable
511.30MUSDFY2025 · Dec 31, 2025Inventory
452.60MUSDFY2025 · Dec 31, 2025Accounts Payable
75.00MUSDFY2025 · Dec 31, 2025Short-term Debt
18.40MUSDFY2025 · Dec 31, 2025Other Current Liabilities
113.80MUSDFY2025 · Dec 31, 2025Long-term Debt
930.80MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
64.20MUSDFY2025 · Dec 31, 2025Common Stock (Book)
100.00KUSDFY2025 · Dec 31, 2025Retained Earnings
287.40MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.52BUSDvs all stocks (USD)
Treasury Stock
60.40MUSDFY2025 · Dec 31, 202552-Week Low
126.40USDUpdated Sep 28, 202652-Week High
354.88USDUpdated Sep 28, 202652-Week Change
-56.17%vs all stocks
Beta
1.08xvs all stocks
50-Day MA
148.31USDUpdated Sep 28, 2026200-Day MA
197.43USDUpdated Sep 28, 2026Avg 10-Day Volume
1.46MSharesUpdated Sep 28, 2026Avg 30-Day Volume
1.63MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
5.32USDUpdated Sep 28, 2026Other Income / Expense
-109.60MUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Low Fixed-Asset Share With Elevated Turnover
It owns few buildings and machines, yet gets more sales and profit from its assets than its industry does.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 26%, higher than 95% of its Medical Devices peers (median 3.2%)Significant
Return on equity: 0.26Industry median: 0.03Industry P95: 0.18Peers compared: 59.00
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.23Receivables vs revenue divergence: 2.37
Financial Health
Altman Z-Score 5.23: safe zoneNotable
Altman Z-Score: 5.23
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $9.44B, above the global median of $1.2BNotable
Market cap (USD): 9,441,187,109Global Median: 1,201,862,193
Revenue is $3.05B, above the global median of $558.46MNotable
Revenue (USD): 3,053,400,064Global Median: 558,459,881.051
Levered free cash flow is $236.9M, above the global median of $18.92MNotable
Levered free cash flow (USD): 236,900,000Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Sichuan Kelun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Arrowhead Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bruker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Nuvalent, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Kalekim Kimyevi Maddeler Sanayi ve Ticaret A.Ş.
7 interpretationsROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverThree Asset-Base Ratios Elevated
Dunelm Group plc
6 interpretationsROE, ROA, And Operating ROA ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverThree Asset-Base Ratios Elevated
Vital Farms Inc.
7 interpretationsROE, ROA, And Operating ROA ElevatedOperating Income Growing With Multi-Year Revenue GrowthMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow Fixed-Asset Share With Elevated TurnoverThree Asset-Base Ratios Elevated